Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1440
    Keywords: Tumor necrosis factor ; Interferon gamma ; Colonic neoplasms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Recombinant human tumor necrosis factor (TNF) is a cytotoxic monokine with immunomodulatory functions. Gamma interferon (g-IFN) synergizes with TNF in many ways. We therefore conducted a Phase I/II combination trial with TNF and g-IFN at an immunomodulatory dose level in 16 patients with colorectal cancer. TNF (50 μg/m2 in a 30 min infusion) and g-IFN (100 μg in subcutaneous injections) were administered daily Monday through Friday for 4 weeks. Two cases of major toxicity, one acute renal failure and one case of severe thrombocytopenia, led to discontinuation of study medication in these patients. Toxicities in remaining patients were manageable with conservative treatment. Changes in laboratory values included leukopenia, anemia and thrombocytopenia. Alterations in lipid metabolism and changes in serum levels of acute phase proteins were observed. Increase in both total lymphocytes and a Leu 11 positive subpopulation, as well as an induction of measurable interleukin 2 serum levels in a subgroup of patients, were noted. Response results of 14 evaluable patients were one patient with a mixed response, 4 with stable disease and 9 with disease progression. Median survival was 23.5 weeks with only one patient alive after 71 weeks. Therefore the drug combination of TNF/g-IFN in the chosen regimen cannot be recommended for the treatment of patients with colorectal cancer.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Langenbeck's archives of surgery 377 (1992), S. 28-33 
    ISSN: 1435-2451
    Keywords: Weichteilsarkome ; Extremitäten und Rumpf ; Klinisches Bild ; Behandlungsmodalitäten ; Prognosefaktoren
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Between 1970 and 1988 surgery was performed on 124 patients with soft tissue sarcomas of the extremities and trunk in the University Clinics of Hamburg. Liposarcoma, malignant fibrous histiocytoma, fibrosarcoma and malignant schwannoma were the most common histological types. High-grade sarcomas (G3) predominated, with 41 %, while 26% were graded G2 and 33% G1. Resection with wide margins all round was achieved in only 54% of the patients. The quality of the operation proved to be only therapy-related prognostic factor. In addition, tumour grade, size, regional lymph node and distant metastasis and histological type proved to be relevant to the prognosis. With multivariate analysis, distant metastasis, grade, resectability and histological type retained prognostic significance. The efficacy of adjuvant chemo- and radiotherapy was related to the quality of the preceding tumour resection. In case of gross tumour the rate of either partial or complete response was 28% for chemotherapy and 22% for radiotherapy. The mean survival time was 102 months; the 5- and 10-year survival rates were 48% and 37%, respectively.
    Notes: Zusammenfassung In der Chirurgischen Universitätsklinik Hamburg wurden von 1970–1988 124 Patienten mit Weichteilsarkomen der Extremitäten und des Rumpfs operiert. Liposarkome, maligne fibröse Histiozytome, Fibrosarkome und maligne Schwannome waren die häufigsten histologischen Typen. Niedrig differenzierte Sarkome (G3) überwogen mit einem Anteil von 41%, während 26% als G2 und 33% als G1 imponierten. Bei nur 54% der Patienten wurde eine Tumorresektion mit dreidimensional weitem Sicherheitsabstand durchgeführt. Dabei stellte sich die Qualität der Operation (RO/1/2) als einziger im Rahmen der Therapie beeinflu\barer Prognosefaktor heraus. Daneben wurde in der univariaten Analyse das Tumorgrading, die Tumorgröße, die regionalen Lymphknoten- und Fernmetastasen und der histologische Typ als prognostisch relevant ermittelt. In der multivariaten Analyse behielten die Faktoren Fernmetastasen, Grading, Resektabilität und histologischer Typ statistische Signifikanz. Der Erfolg einer adjuvanten Chemo- und Strahlentherapie war erheblich von der Qualität der vorangegangenen Tumorresektion abhängig. Bei klinisch manifestem Tumor wurde mit einer Chemotherapie bei 28% der Fälle eine Voll- oder Teilremission erreicht, mit einer Strahlentherapie bei 22% der Fälle. Die durchschnittliche Überlebenszeit betrug 102 Monate, die 5- und 10-Jahres-Überlebensrate 48% bzw. 37%.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0584
    Keywords: Translocation (14,18) and (8,22) ; Leukemia ; NHL
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Three patients with centrocytic/centroblastic lymphoma developed a rapidly fatal leukemic transformation of the disease after a transient remission. At the time of transformation, cytogenetic analysis revealed in all patients abnormal karyotypes with coexistence of t (14; 18) and t (8; 22). Molecular analysis in one patient showed rearrangement of the BCL2 oncogene and c-myc m-RNA expression. These findings imply that translocation t (14; 18) was present during the first phase of the disease and that acquisition of translocation t (8; 22) was accompanied by leukemic transformation.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0584
    Keywords: Multiple myeloma ; Plasma cell leukemia ; Cytogenetics ; Cytology
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Cytogenetic studies in patients with multiple myeloma (MM) and plasma cell leukemia (PCL) have in general been largely unsuccessful. The investigation of mitoses of nonmalignant hematopoietic precursor cells, rather than mitoses of malignant plasma cells might account for the low percentage of pathological genetic findings. We investigated bone marrow (BM) cells of 51 patients both cytogenetically and cytologically. In patients with a normal karyotype (n=39) nearly all mitoses examined cytologically (107/117) derived from granulopoietic or erythropoietic cell lineages. In contrast, 20/27 metaphases in patients with a pathological karyotype (n=12) were found to be plasma cell mitoses. These findings may explain the low rate of chromosomal rearrangements in MM and may suggest that the real abnormality rate is considerably higher.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1432-0584
    Keywords: Acute myeloid leukemia ; Acute promyelocytic leukemia ; Acute myelomonocytic leukemia ; t (15, 17) ; inv(16)
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Acute promyelocytic leukemia (AML FAB M3, APL) and acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) are considered distinct entities with characteristic clinical, morphological, cytogenetic, and prognostic features. Promyelocytic leukemia is characterized by abnormal promyelocytes replacing normal hematopoiesis associated with a translocation between the long arms of chromosomes 15 and 17 t (15; 17), severe coagulopathy, and responsiveness to all-trans retinoic acid (tretinoin). Characteristic features of AML M4Eo are a myelomonocytic marrow infiltration, eosinophils with abnormal immature granules positive for chloroacetate esterase, an inversion or translocation of chromosome 16, and an increased risk of meningeal relapses. Prognosis of both types of AML has been reported to be better than prognosis of the other entities combined. Since most of the published data were collected from heterogeneous patient populations treated with various chemotherapeutic regimens, we have analyzed treatment outcome of AML M3 and M4Eo in the AMLCG-85 study for patients younger than 60 years. For the total population of 594 patients of this study, CR rate was 68.89%, early death rate 11.60%, and no or partial remission was achieved in 19.51% of the cases. Of 40 patients with AML M3 or M3v complete remission was attained in 62.5%. Nine patients died within 42 days after the start of antileukemic therapy (22.5%). Of these nine, four died because of infection, five because of bleeding. Relapse-free survival rate was 59% after 3 years, significantly better than the respective curve of the other FAB types combined (35% after 3 years). In AML M4Eo, 91.7% of the 24 patients reached complete remission. The early death rate was 8.3%. No case of nonresponse was seen. Relapse-free survival rate was 49% after 3 years compared with 35% for the other types combined.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1432-0584
    Keywords: Ph1+-ALL ; Prognosis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Between 1983 and 1991 the Philadelphia chromosome (Ph1) was found in bone marrow and/or peripheral blood cells of 25 adult patients with acute lymphoblastic leukemia (ALL). The Ph1 as sole anomaly was seen in 13 patients, while six patients had additional structural and another six structural and numerical aberrations. Most patients (23/25) received combination chemotherapy according to the BMFT protocols 1/81, 2/84, 3/87, and 4/89. For 25 evaluable patients two early deaths, two treatment failures, two partial remissions (PR), and 19 complete remissions (CR) after phase 1 or 2 of the induction regimen were recorded. Two of these 19 patients who achieved CR are presently disease free, whereas 17 have relapsed after a median duration of remission of 9 months. Actuarial median survival for all patients was 13 months. The probability of continuous complete remission (CCR) after 39 months, as well as that of survival after 40 months, is only 6%. Our results confirm that the presence of the Ph1 is associated with a poor prognosis in adult-ALL patients. Therefore, whenever first CR is obtained and an HLA-identical donor is available, allogeneic bone marrow transplantation (BMT) should be performed at once, the more so, since transplantation in second CR seems to offer no cure. Future studies will have to show whether an intensified cytotoxic therapy can improve the prognosis of Ph1+-ALL.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...